Tyler Saavedra-Buckley

Cooley advised Veritone, a company building human-centered enterprise artificial intelligence (AI) solutions, on the sale of its media agency, Veritone One, to Insignia Capital Group.

Cooley advised Harvey, a legal artificial intelligence platform, on its $100 million Series C financing, which brings Harvey to a $1.5 billion valuation.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Cooley advised Rubicon Technology Partners – a Boulder, Colorado-based private equity firm focused exclusively on investing in and growing software companies – on its majority strategic investment in Vimly Benefit Solutions, a leader in the benefits administration space.